Galmed Pharmaceuticals (GLMD) FCF Payout Ratio Growth (3y) (2016 - 2023)
Galmed Pharmaceuticals (GLMD) FCF Payout Ratio Growth (3y) (2016 - 2023) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Cover Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 9.12% |
| 10 | Galmed Pharmaceuticals | 2.31 Mn | -9.57 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2023 | 30.97% |
| Mar 31, 2022 | 53.49% |
| Mar 31, 2020 | -68.08% |
| Sep 30, 2019 | 52.13% |
| Jun 30, 2019 | 328.95% |
| Mar 31, 2019 | -113.59% |
| Sep 30, 2018 | -119.98% |
| Jun 30, 2018 | 8.37% |
| Mar 31, 2018 | 9.89% |
| Sep 30, 2017 | -31.97% |
| Jun 30, 2017 | -26.63% |
| Mar 31, 2017 | 71.21% |
| Sep 30, 2016 | -99.57% |
| Jun 30, 2016 | -64.31% |
| Mar 31, 2016 | -20.17% |